Financial Performance - For the full year 2025, Globus Medical reported revenue of $2.939 billion, representing a growth of 16.7% year-over-year, and non-GAAP earnings per share (EPS) of $3.98, up 30.8% [4][22] - In Q4 2025, revenue reached $826.4 million, a 25.7% increase compared to Q4 2024, with non-GAAP EPS of $1.28, growing 52.1% year-over-year [5][23] - The base business revenue for Q4 was $726.7 million, reflecting a 10.6% growth compared to the same quarter last year [5][25] - Adjusted EBITDA margin for Q4 was 35.7%, while the full year margin was 33.4% [6][24] Business Line Performance - The U.S. spine business grew by 10% in Q4 compared to the prior year quarter, continuing a trend of above-market growth [6][27] - Enabling Technologies revenue was $55.6 million in Q4, growing 18.5% year-over-year, driven by increased sales of EGPS systems [11][26] - The trauma business experienced approximately 27% growth in Q4, supported by the legacy trauma line and precise limb lengthening products [15][16] Market Performance - U.S. revenue in Q4 was $665.3 million, growing 27.5% year-over-year, while international revenue was $161.1 million, reflecting a 19% increase [26][27] - The international spine business faced supply chain challenges earlier in the year but showed improvement, culminating in record sales in Q4 2025 [28][80] Company Strategy and Industry Competition - The company aims to penetrate and launch new programs while fostering utilization and service excellence across its install base [14] - Globus Medical is focused on expanding its core spine business while also growing adjacent markets through innovation and product development [18][19] - The company views competition in the enabling technology space as evolving but believes its ExcelsiusGPS system remains a strong offering [12][69] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in the sustainability of U.S. spine growth, citing product launches and a robust sales force as key drivers [68] - The company anticipates continued margin expansion and has set a long-term goal for mid-seventies adjusted gross profit percentage [30][43] - Management acknowledged the challenges faced in international markets but remains optimistic about returning to double-digit growth rates [80] Other Important Information - The company repurchased approximately 4.3 million shares during 2025, with a remaining authorization of $390 million under its share repurchase program [37][38] - Research and development expenses for Q4 were $36.2 million, or 4.4% of sales, reflecting a decrease from the prior year [30][32] Q&A Session Summary Question: Can you bridge the growth expectations for the base business into 2026? - Management noted that 2025 was a tale of two halves, with significant growth in the latter half driven by product launches and sales force expansion [47][48] Question: How do you view market share and the strength of the spine market? - Management believes the U.S. spine business is growing above market and views the overall spine market as relatively healthy [54] Question: What changed in the enabling technology environment? - Management indicated that enabling technology performance was lumpy throughout the year, with a strong Q4 driven by closing delayed pipeline deals [59][60] Question: How sustainable is the U.S. spine growth? - Management sees the growth as durable, supported by ongoing product launches and competitive rep conversions [68][69] Question: What are the headwinds in the international market? - Management highlighted that the international business can grow 12%-15% long-term, with a focus on deepening existing markets rather than expanding into new ones [80]

Merit Medical Systems (NasdaqGS:MMSI) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Speaker10Welcome to the Merit Medical Systems fourth quarter 2025 earnings conference call. At this time, all participants have been placed in listen-only mode. Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly. I would now like to turn the call over to Martha Aaronson, Merit Medical Systems President and Chief Executive Officer. ...

Core Insights - The Chinese medical device industry has undergone significant transformation since the country joined the WTO in 2001, leading to the establishment of a comprehensive network of sales, service, and training by multinational manufacturers [1][2] - The domestic production of medical devices has increased dramatically, with the localization rate of monitoring devices exceeding 85%, and the market share of Chinese medical devices in the global market is on the rise [2][3] - China's medical device sector is projected to grow, with over 35,000 production companies expected by the end of 2025 and a market size estimated to reach 1.22 trillion yuan [2] Industry Development - The medical device sector is a crucial pillar of healthcare, alongside medical services and pharmaceuticals, encompassing a wide range of products including diagnostic equipment and implants [1] - The emergence of numerous startups focused on independent research and development of medical devices has been driven by market demand [1] - The Chinese manufacturing industry has developed capabilities across nearly all categories of medical devices, with significant advancements in innovative products such as ECMO [3] Technological Advancements - The integration of advanced technologies such as artificial intelligence and 5G is expected to drive the next wave of innovation in medical devices, enabling new diagnostic and treatment methods [4] - The establishment of research and development centers by foreign companies in China highlights the strategic importance of the local market and supply chain [3] Market Dynamics - China's large population and diverse health needs are accelerating the pace of technological iteration in the global medical device industry [2] - The shift from "following" to "competing" and even "leading" in certain areas reflects the industry's evolution and the rise of "China Intelligent Manufacturing" [3]

深圳开立生物医疗科技公司业务经理表示："依托班列的稳定服务和定制化方案，我们的精密医疗设备 才能安全、准时送达欧洲客户手中。" 平湖南综合物流枢纽营业部经理罗练林表示："我们将构建更高效、便捷的国际物流平台，进一步降低 企业跨境贸易的综合成本。" 本报深圳2月24日电(记者李刚)2026年农历正月初一早上8时许，一声汽笛在深圳平湖南站鸣响，满载家 电、电子产品及跨境电商包裹的X8426次中欧班列，迎着新春朝阳启程，奔赴满洲里口岸，预计14天后 抵达俄罗斯、波兰等国家。 这趟新春首发的中欧班列是粤港澳大湾区外贸物流"开年第一单"。自2020年8月18日首趟"湾区号"中欧 班列从深圳开往德国杜伊斯堡以来，截至目前已累计开行975列，运送货物超9万标箱，货值突破31亿美 元，线路从1条增至27条常态化线路，覆盖德国、俄罗斯等47个国家和地区，服务大湾区企业超7000 家。 ...

转自：贵州日报 2月24日，在山东省烟台市芝罘区只楚街道一家制冷设备和换热装置制造企业，工人在生产线上忙碌。 新华/传真 2月24日，正月初八，开工! 春节假期后首个工作日，多地以"新春第一会"吹响奋进号角，重大项目开工蹄疾步稳，企业生产线开足 马力赶订单、保供应，"十五五"开局之年，奋力跑出万马奔腾的昂扬气势。 凝心聚力，绘就全年"施工图" 正月初八，岭南春早。2026年广东省高质量发展大会如约而至，这是广东连续四年在春节后首个工作日 举办高质量发展大会。 从明确"再造一个新广东"的目标，到创新驱动、现代化产业体系建设，再到今年"制造业与服务业协同 发展"，广东"新春第一会"的主题年年深入，一以贯之推动高质量发展。 春节假期节后首日，多地"新春第一会"召开，以"开局即冲刺"的姿态绘就全年"施工图"，为高质量发展 部署"任务书"。 江淮腹地，合肥"新春第一会"聚焦"科技创新引领新质生产力发展"。科研人员、企业家、基层干部齐聚 一堂，共商创新之策。"'新春第一会'再次强调科技创新，让我们充满信心，新的一年企业将坚持以实 干争先，以创新赋能。"蔚来汽车创始人李斌说。 三湘大地，湖南省召开全省促进民营经济发展壮大暨 ...

证券代码：688108 证券简称：赛诺医疗 公告编号：2026-012 赛诺医疗科学技术股份有限公司 结构及组成：颅内取栓支架由取栓网架、显影装置、推送杆、鞘管及显影丝等组成。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 赛诺医疗科学技术股份有限公司（以下简称"赛诺医疗"或"公司"） 控股子公司赛诺神畅医疗科技有限 公司（以下简称"赛诺神畅"）于2024年向欧盟公告机构递交了公司Ghunter颅内取栓支架按照欧盟医疗 器械法规Medical Devices Regulation（EU）2017/745（简称"MDR"）注册认证的申报资料。赛诺神畅于 近日收到欧盟公告机构通知，Ghunter颅内取栓支架获得按照欧盟MDR法规签发的欧盟CE MDR认证。 现将相关情况公告如下： 一、注册证内容 证书名称：EU Quality Management System Certificate、 EU Technical Documentation Assessment Certificate 证书编号：229146 ...

Establishment Labs (NasdaqCM:ESTA) Q4 2025 Earnings call February 24, 2026 08:30 AM ET Company ParticipantsAllen Gong - VP and Equity ResearchAnthony Petrone - Managing Director Equity ResearchPeter Caldini - Board of DirectorsRaj Denhoy - CFOConference Call ParticipantsCaitlin Cronin - Director and Equity AnalystJoshua Jennings - Managing Director and Senior AnalystMason Carrico - Research AnalystMike Matson - Senior AnalystSam Eiber - VP and Medical Technology AnalystSam Eiber - Vice President and Medical ...

Orthofix Medical (NasdaqGS:OFIX) Q4 2025 Earnings call February 24, 2026 08:30 AM ET Company ParticipantsJulie Andrews - CFOJulie Dewey - Chief Investor Relations and Communications OfficerMassimo Calafiore - President and CEOMathew Blackman - Managing DirectorMichaela Smith - Equity Research AssociateTom Stephan - AVPConference Call ParticipantsMike Petusky - Managing Director and Senior Research AnalystOperatorThank you. I would now like to turn the call over to Julie Dewey.Julie DeweyThank you, operator, ...

Establishment Labs (NasdaqCM:ESTA) Q4 2025 Earnings call February 24, 2026 08:30 AM ET Company ParticipantsAllen Gong - VP and Equity ResearchAnthony Petrone - Managing Director Equity ResearchPeter Caldini - Board of DirectorsRaj Denhoy - CFOConference Call ParticipantsCaitlin Cronin - Director and Equity AnalystJoshua Jennings - Managing Director and Senior AnalystMason Carrico - Research AnalystMike Matson - Senior AnalystSam Eiber - VP and Medical Technology AnalystSam Eiber - Vice President and Medical ...

Financial Data and Key Metrics Changes - Total global net sales in Q4 reached $218.6 million, a 3% increase supported by strong performances in Bone Growth Therapies and U.S. limb reconstruction segments [12] - Pro forma non-GAAP adjusted gross margin was 71.4%, reflecting the impact of the M6 discontinuation and productivity improvements [15] - Fourth quarter pro forma non-GAAP adjusted EBITDA was $29.2 million, or 13.4% of net sales, with year-over-year margin expansion of approximately 230 basis points [15] - Free cash flow for Q4 was exceptionally strong at $16.8 million, demonstrating the strength and scalability of the business model [15] Business Line Data and Key Metrics Changes - Global spine fixation Q4 net sales grew 10% for the year and in Q4, with U.S. spine fixation net sales growing 6% for the year and 5% for the quarter [4] - Bone Growth Therapies (BGT) net sales were $68.3 million, up 7%, significantly outperforming the market [13] - U.S. limb reconstruction sales were $38 million in Q4, driven by 8% U.S. growth [14] Market Data and Key Metrics Changes - U.S. limb reconstruction grew 8% in Q4 and 16% for the full year, driven by successful product launches [7] - The spine commercial channel optimization efforts led to a 25% year-over-year growth in net sales from the top 30 U.S. distributor partners [5] Company Strategy and Development Direction - The company has rebranded its orthopedics business as limb reconstruction, focusing on four high-value clinical categories, representing an estimated $2.6 billion market opportunity [6] - The full market release of the VIRATA Spinal Fixation System is anticipated in the second half of 2026, expected to enhance surgical efficiency and serve as a multi-year growth catalyst [6] - The company is recalibrating its three-year financial targets to fully capture the anticipated benefits of its spine commercial channel optimization [9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about entering 2026 with strong momentum and a solid foundation for growth, driven by new product launches and improved distributor performance [11] - The company expects to deliver durable top-line growth, expanding margins, and strong free cash flow in 2026 [9] - Management highlighted the importance of disciplined execution and targeted capital deployment to create sustainable long-term shareholder value [22] Other Important Information - The company expects full-year net sales of $850 million-$860 million for 2026, representing implied pro forma constant currency year-over-year growth of approximately 5.5% [16] - Adjusted growth margins for the full year are expected to be approximately 72.5% [19] Q&A Session Summary Question: Clarification on CMS impact on BGT - Management clarified that the CMS change will have about a 1% impact in Q1 specific to BGT revenue only [31] Question: Long-range plan (LRP) and margin improvement - Management indicated that the delay in the LRP reflects the extensive work done to strengthen the foundation and optimize the distributor transition [32][33] - They emphasized the focus on gross margin expansion and productivity improvements to achieve mid-teens EBITDA and positive free cash flow [35] Question: 2026 revenue guidance specifics - Management expects above-market growth for BGT and limb reconstruction, with U.S. limb reconstruction returning to double-digit growth in the second half of 2026 [40] Question: 7D placements and biologics portfolio - Management reported a 30% increase in 7D placements in 2025 and expressed confidence in the biologics portfolio's potential for recovery and growth [48][50] Question: Tariff impact and legal settlements - Management confirmed that the tariff impact is included in the 2026 guidance, expecting about $1 million-$2 million impact [54] - They acknowledged having taken an accrual for a legal settlement in Q3 [56]